908 Devices Inc. (MASS) AI Stock Analysis
MASS AI stock analysis summary
AI Research908 Devices Inc. (NASDAQ: MASS) develops handheld and desktop mass spectrometry devices for life sciences, bioprocessing, and forensics. The company generated $60.8M in trailing twelve-month revenue with quarterly sales growth of 23.3%, though it remains unprofitable with an operating margin of -39.6%. 908 Devices maintains a liquid balance sheet with $97.2M in net cash as of June 30, 2026.
- Market cap
- $465.4M
- Revenue (TTM)
- $60.8M
- P/E
- —
- 1Y return
- 29.7% S&P 500 16.8%
- Avg. target
- $13.38 18.8% vs last close
Bull case
- Revenue expanded 23.3% year-over-year in the quarter ended June 30, 2026, following a 5-year revenue CAGR of 15.9%.
- The balance sheet is well capitalized with $101.5M in cash and short-term investments against just $4.3M in total debt.
- The stock has beaten consensus EPS expectations in each of the past 4 quarters, and analysts project revenue to reach $82.5M next fiscal year.
Bear case
- The company continues to produce losses, recording a net loss of -$36.6M in FY2025 and a trailing twelve-month profit margin of -57.0%.
- Free cash flow remained negative at -$24.6M in FY2025, driven by ongoing operational cash burn of -$23.7M.
- Valuation multiples are elevated relative to industry benchmarks, with a price-to-sales multiple of 7.6x versus the US-listed Healthcare median of 4.1x.
What 908 Devices does
908 Devices Inc. is a commercial-stage technology company specializing in purpose-built handheld and desktop mass spectrometry (Mass Spec) devices. Its instruments analyze unknown materials for life sciences research, bioprocessing, industrial biotech, and forensics. Core offerings include the MX908, a handheld device for rapid analysis of gas, liquid, and solid materials; the Rebel, a compact desktop analyzer monitoring the extracellular environment in bioprocesses; and the ZipChip platform, a plug-and-play solution for high-resolution sample separation. Based in Boston, Massachusetts, the company operates across the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions.
Growth and profitability
Annual revenue grew at a 5-year CAGR of 15.9% from FY2020 through FY2025. Revenue expanded from $42.2M in FY2021 to $59.6M in FY2024 before decreasing 5.8% to $56.2M in FY2025. Gross margin contracted from 55.0% in FY2021 to 47.7% in FY2025. The company posted net losses across each period, including -$72.2M in FY2024 and -$36.6M in FY2025. For the trailing twelve months ended June 30, 2026, revenue stood at $60.8M with a profit margin of -57.0% and EPS of -$0.94, supported by a 23.3% year-over-year revenue increase in the latest quarter.
Balance sheet and cash flow
As of June 30, 2026, 908 Devices held $101.5M in cash and short-term investments alongside total debt of $4.3M, leaving net cash at $97.2M. The company reported a current ratio of 2.67 and a debt-to-equity ratio of 0.03 against shareholders' equity of $126.8M. Operating cash flow remained negative at -$23.7M in FY2025, resulting in free cash flow of -$24.6M after capital expenditures of $955,000. Over five years, its share count increased by 28.0%.
Valuation and performance
908 Devices trades at a price-to-sales multiple of 7.6x and an enterprise value to revenue multiple of 5.8x, compared to the median of 4.1x price-to-sales for its US-listed Healthcare peers. Its price-to-book ratio stands at 3.6x. Over the past year, the stock appreciated 29.7%, exceeding the S&P 500 (SPY) gain of 16.8%. Over a 5-year period, however, MASS generated a return of -64.9%, while the S&P 500 gained 83.0%. The stock's beta is 0.62.
What analysts expect
Consensus ratings include 6 Strong Buy ratings with zero Buy, Hold, or Sell recommendations. The mean price target is $13.38, representing an 18.8% upside from the October 16, 2026 close of $11.26. For the fiscal year ending December 31, 2026, analysts estimate revenue of $69.1M and an EPS of -$0.48. For the next fiscal year, 4 analysts project revenue of $82.5M, representing 19.4% growth, and EPS of -$0.31. The company beat EPS estimates in each of the last 4 quarters, with next earnings scheduled for November 9, 2026.
Key risks and what to watch
- Persistent operational cash burn of -$23.7M in FY2025 could eventually deplete cash balances if profitability is not attained.
- Gross margins have drifted lower from 55.0% in FY2021 to 47.7% in FY2025.
- Short interest represents 12.8% of the float, indicating elevated negative sentiment among certain market participants.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this MASS AI stock analysis
This page is an AI-written research summary of 908 Devices Inc. (MASS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: MASS income statement, MASS balance sheet, MASS key metrics, MASS analyst forecast, MASS chart. See the MASS stock overview for the latest quote and news.
MASS AI stock analysis FAQ
What products does 908 Devices manufacture?
908 Devices develops handheld and desktop mass spectrometry tools. Key offerings include the MX908 handheld analyzer, the Rebel desktop bioprocess analyzer, and the ZipChip high-resolution sample separation platform.
Is 908 Devices profitable?
No, the company is not currently profitable. In FY2025, 908 Devices reported a net loss of -$36.6M and an operating cash outflow of -$23.7M, while its trailing twelve-month profit margin is -57.0%.
How much cash does 908 Devices have on hand?
As of June 30, 2026, the company held $101.5M in cash and short-term investments. With total debt at $4.3M, it had net cash of $97.2M.
Does MASS stock pay a dividend?
No, 908 Devices does not pay a dividend. Cash is directed toward funding operations, research and development, and business growth.